EUVIMEDEUVIMED entdecken
CrossrefInfokarte

4-Octyl itaconate suppresses IFN-γ–induced MHC II expression in bone marrow–derived macrophages

Zhiying Zhou, Yixiu Ni, Shanshan Huang, Yijia Lin, Mingkun Yang, Yingwei Wu, Guolong Cai, Zhouxin Yang

The Journal of Immunology · 2026-10-01 · 215 (10)

DOI: 10.1093/jimmun/vkag255 ↗
AbstractBibliografische Angaben

Abstract

Abstract Macrophages function as professional antigen-presenting cells that integrate inflammatory signals with metabolic reprogramming to shape immune responses. Itaconate, an immunometabolite derived from ACOD1/IRG1 activity in activated macrophages, has been implicated in the regulation of inflammatory responses, yet its role in interferon γ (IFN-γ)–driven antigen presentation programs remains incompletely understood. Here, we demonstrate that the itaconate derivative 4-octyl itaconate (4-OI) suppresses IFN-γ–induced antigen presentation programs in bone marrow-derived macrophages. 4-OI reduced surface major histocompatibility complex class II (MHC II) expression and downregulated key components of the antigen presentation machinery, including CIITA, H2-Ab1, and H2-Eb1. Transcriptomic analysis revealed broad suppression of IFN-γ–responsive immune pathways, particularly those associated with antigen processing and inflammatory signaling. Mechanistically, 4-OI attenuated IFN-γ–induced phosphorylation of JAK1, JAK2, and STAT1, and pharmacological inhibition of JAK signaling phenocopied its effects on MHC II expression, implicating involvement of the IFN-γ–JAK–STAT1–CIITA axis. In vivo, 4-OI similarly reduced IFN-γ–induced MHC II expression in splenic macrophages, accompanied by decreased PD-L1 expression as a parallel marker of macrophage activation. Together, these findings identify 4-OI as an immunometabolic regulator of IFN-γ–driven macrophage activation, associated with modulation of the JAK–STAT1–CIITA signaling axis and suppression of antigen presentation programs.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →